Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Overview of attention for article published in Lancet Oncology, February 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 6 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 27 X users

patent: 87 patents
facebook: 5 Facebook pages
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 882 Mendeley

So far, Altmetric has seen 5 public wall posts from 5 users.

Clinical Oncology Pharmacy (د. نجوي ابراهيم), 21 Mar 2015

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-s…

Oncología Canarias, 19 Mar 2015

Activity and safety of nivolumab (anti-PD-1) for advanced, refractory squamous NSCLC: a phase 2, single-arm trial http://t.co/e0W…

ALCASE Italia - Per la Lotta al Cancro del Polmone, 12 Mar 2015

DALLA LETTERATURA MEDICO-SCIENTIFICA Come dicevamo nei giorni scorsi, il Nivolumab (http://www.alcase.it/educational/premessa-far…

Journal Club for Basic Bio-Medical Sciences & Clinical Medicine, 02 Mar 2015

Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 1 additional Facebook posts.